Egyszerű nézet

dc.contributor.author Reusz, György
dc.contributor.author Szabó, Attila
dc.contributor.author Reti M
dc.contributor.author Gyorke Z
dc.contributor.author Szilágyi, Ágnes
dc.contributor.author Farkas, Péter
dc.contributor.author Prohászka, Zoltán
dc.date.accessioned 2015-04-17T18:26:31Z
dc.date.available 2015-04-17T18:26:31Z
dc.date.issued 2011
dc.identifier 79957615728
dc.identifier.citation pagination=1247-1249; journalVolume=43; journalIssueNumber=4; journalTitle=TRANSPLANTATION PROCEEDINGS;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/1572
dc.identifier.uri doi:10.1016/j.transproceed.2011.03.071
dc.description.abstract BACKGROUND: Hemolytic uremic syndrome (HUS) is a rare disease with various etiologies, making the identification of the specific forms and appropriate treatment difficult. Therefore, clinical and laboratory data from these patients need to be analyzed in national and international registries. Herein we have described 47 Hungarian HUS patients with detailed laboratory and clinical data obtained between 2008 and 2010. METHODS: Blood samples and clinical data of 47 patients with HUS diagnosed according to characteristic clinical signs were submitted for diagnostic evaluation, including complement protein and genetic analysis, measurement of ADAMTS13 activity and antibody analysis against O157LPS and factor H. RESULTS: There were 8 patients with typical diarrhea-positive HUS; 13 with atypical HUS (aHUS) and 26 with secondary HUS/thrombotic thrombocytopenic purpura group characterized by signs of complement consumption and decreased ADAMTS13 activity. Thus, decreased total alternative pathway activity is a promising diagnostic parameter with good sensitivity for aHUS. CONCLUSIONS: These observations highlight the requirement for multiple diagnostic tests together with clinical data to identify the specific cause of HUS. Because the long-term prognosis of aHUS, eg, graft survival after renal transplantation, may vary according to the molecular etiology, it is important for all affected patients to undergo a detailed molecular diagnosis of the disease. There is a clear clinical need for the development and application of novel assay in this field to allow more rapid efficient diagnosis of patients who undergo a first episode of HUS.
dc.relation.ispartof urn:issn:0041-1345
dc.title Diagnosis and classification of hemolytic uremic syndrome
dc.type Journal Article
dc.date.updated 2015-03-13T10:07:10Z
dc.language.rfc3066 en
dc.identifier.mtmt 1608373
dc.identifier.wos 000291289400078
dc.identifier.pubmed 21620101
dc.contributor.department SE/AOK/K/I. Sz. Gyermekgyógyászati Klinika
dc.contributor.department MTA TKI/MTA-SE Gyulladásbiológiai és Immungenomikai Kutatócsoport (2006-ig: MTA-SE Molekuláris Immunológiai Kutatócsoport)
dc.contributor.department SE/AOK/K/III. Sz. Belgyógyászati Klinika
dc.contributor.institution Semmelweis Egyetem
dc.contributor.institution MTA Támogatott Kutatócsoportok


Kapcsolódó fájlok:

A fájl jelenleg csak egyetemi IP címről érhető el.

Megtekintés/Megnyitás

Ez a rekord az alábbi gyűjteményekben szerepel:

Egyszerű nézet